A
A. Craig Lockhart
Researcher at University of Miami
Publications - 116
Citations - 6712
A. Craig Lockhart is an academic researcher from University of Miami. The author has contributed to research in topics: Cancer & Esophageal cancer. The author has an hindex of 35, co-authored 110 publications receiving 5349 citations. Previous affiliations of A. Craig Lockhart include Washington University in St. Louis & Duke University.
Papers
More filters
Journal ArticleDOI
Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in Oncology
Jaffer A. Ajani,Thomas A. D'Amico,Khaldoun Almhanna,David J. Bentrem,Joseph Chao,Prajnan Das,Crystal S. Denlinger,Paul T. Fanta,Farhood Farjah,Charles S. Fuchs,Hans Gerdes,Michael K. Gibson,Robert E. Glasgow,James A. Hayman,Steven N. Hochwald,Wayne L. Hofstetter,David H. Ilson,Dawn E. Jaroszewski,Kimberly L. Johung,Rajesh N. Keswani,Lawrence Kleinberg,W. Michael Korn,Stephen Leong,Catherine Linn,A. Craig Lockhart,Quan P. Ly,Mary F. Mulcahy,Mark B. Orringer,Kyle A. Perry,George A. Poultsides,Walter J. Scott,Vivian E. Strong,Mary Kay Washington,Benny Weksler,Christopher G. Willett,Cameron D. Wright,Debra Zelman,Nicole R. McMillian,Hema Sundar +38 more
TL;DR: The recommendations outlined in the NCCN Guidelines for staging, assessment of HER2 overexpression, systemic therapy for locally advanced or metastatic disease, and best supportive care for the prevention and management of symptoms due to advanced disease are discussed.
Journal ArticleDOI
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Timothy M. Nywening,Andrea Wang-Gillam,Dominic E. Sanford,Brian A. Belt,Roheena Z. Panni,Brian Cusworth,Adetunji T. Toriola,Rebecca Nieman,Lori A. Worley,Motoyo Yano,Kathryn J. Fowler,A. Craig Lockhart,Rama Suresh,Benjamin R. Tan,Kian-Huat Lim,Ryan C. Fields,Steven M. Strasberg,William G. Hawkins,David G. DeNardo,S. Peter Goedegebuure,David C. Linehan +20 more
TL;DR: This trial aimed to establish the safety, tolerability, and recommended phase 2 oral dose of the CCR2 inhibitor PF-04136309 in combination with FOLFIRINOX chemotherapy (oxaliplatin and irinotecan plus leucovorin and fluorouracil) and analysed the primary outcome by intention to treat.
Journal ArticleDOI
Gastric Cancer, Version 2.2013
Jaffer A. Ajani,David J. Bentrem,Stephen Besh,Thomas A. D'Amico,Prajnan Das,Crystal S. Denlinger,Marwan Fakih,Charles S. Fuchs,Hans Gerdes,Robert E. Glasgow,James A. Hayman,James A. Hayman,Wayne L. Hofstetter,David H. Ilson,Rajesh N. Keswani,Lawrence Kleinberg,Lawrence Kleinberg,W. Michael Korn,A. Craig Lockhart,Kenneth L. Meredith,Mary F. Mulcahy,Mark B. Orringer,Mark B. Orringer,James Posey,Aaron R. Sasson,Walter J. Scott,Vivian E. Strong,Thomas K. Varghese,Graham W. Warren,Mary Kay Washington,Christopher G. Willett,Cameron D. Wright,Nicole R. McMillian,Hema Sundar +33 more
TL;DR: The NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer provide evidence- and consensus-based recommendations for a multidisciplinary approach for the management of patients with gastric cancer.
Journal ArticleDOI
Esophageal and esophagogastric junction cancers, version 1.2015.
Jaffer A. Ajani,Thomas A. D'Amico,Khaldoun Almhanna,David J. Bentrem,Stephen Besh,Joseph Chao,Prajnan Das,Crystal S. Denlinger,Paul T. Fanta,Charles S. Fuchs,Hans Gerdes,Robert E. Glasgow,James A. Hayman,Steven N. Hochwald,Wayne L. Hofstetter,David H. Ilson,Dawn E. Jaroszewski,Kory Jasperson,Rajesh N. Keswani,Lawrence Kleinberg,W. Michael Korn,Stephen Leong,A. Craig Lockhart,Mary F. Mulcahy,Mark B. Orringer,James Posey,George A. Poultsides,Aaron R. Sasson,Walter J. Scott,Vivian E. Strong,Thomas K. Varghese,Mary Kay Washington,Christopher G. Willett,Cameron D. Wright,Debra Zelman,Nicole R. McMillian,Hema Sundar +36 more
TL;DR: This portion of the NCCN Guidelines for Esophageal and EGJ Cancers discusses management of locally advanced adenocarcinoma of the esophagus andEGJ.
Journal ArticleDOI
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.
Manish A. Shah,Takashi Kojima,Daniel Hochhauser,Peter C. Enzinger,Judith Raimbourg,Antoine Hollebecque,Florian Lordick,Sung Bae Kim,Masahiro Tajika,Heung Tae Kim,A. Craig Lockhart,Hendrik Tobias Arkenau,Farid El-Hajbi,Mukul Gupta,Per Pfeiffer,Qi Liu,Jared Lunceford,S. Peter Kang,Pooja Bhagia,Ken Kato +19 more
TL;DR: Where effective treatment options are an unmet need, pembrolizumab provided durable antitumor activity with manageable safety in patients with heavily pretreated esophageal cancer.